EntryPoint Capital LLC Takes $684,000 Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

EntryPoint Capital LLC acquired a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 49,886 shares of the company’s stock, valued at approximately $684,000. EntryPoint Capital LLC owned approximately 0.05% of Myriad Genetics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MYGN. Vanguard Group Inc. increased its position in shares of Myriad Genetics by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 10,591,043 shares of the company’s stock valued at $145,203,000 after buying an additional 279,379 shares in the last quarter. State Street Corp increased its holdings in Myriad Genetics by 8.3% during the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after acquiring an additional 359,685 shares in the last quarter. Disciplined Growth Investors Inc. MN raised its position in Myriad Genetics by 21.1% during the third quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock worth $69,226,000 after acquiring an additional 440,107 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Myriad Genetics by 7.4% in the fourth quarter. Sei Investments Co. now owns 2,526,761 shares of the company’s stock valued at $34,642,000 after purchasing an additional 174,770 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its position in shares of Myriad Genetics by 153.7% in the third quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company’s stock valued at $59,973,000 after purchasing an additional 1,326,497 shares during the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics Trading Down 0.3 %

Shares of MYGN opened at $9.98 on Tuesday. Myriad Genetics, Inc. has a twelve month low of $9.36 and a twelve month high of $29.30. The firm has a market capitalization of $911.26 million, a P/E ratio of -7.68 and a beta of 1.79. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The stock’s fifty day simple moving average is $12.05 and its 200 day simple moving average is $16.92.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The firm had revenue of $210.60 million during the quarter, compared to analysts’ expectations of $210.35 million. During the same quarter last year, the business earned ($0.12) earnings per share. On average, equities research analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Stephens reaffirmed an “equal weight” rating and issued a $20.00 target price on shares of Myriad Genetics in a research note on Thursday, January 16th. Raymond James restated an “outperform” rating and issued a $19.00 price objective (down from $27.00) on shares of Myriad Genetics in a research report on Tuesday, February 25th. StockNews.com cut Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, March 13th. Bank of America reduced their target price on shares of Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a report on Monday, March 3rd. Finally, UBS Group lowered their price target on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, February 25th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $21.89.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.